Metabotropic glutamate receptor as therapeutic targets

Drug News and Perspectives

Volumn 18, Issue 9, 2005, Pages 587-593

  Guitart, X ^a   Khurdayan, V K ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; 2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; ADX 47273; AMN 082; BAY 36 7620; EGLUMETAD; LORAZEPAM; LY 314582; LY 314593; LY 404039; LY 456236; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR 7; METABOTROPIC RECEPTOR 8; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; NPS 2390; PRE 073; PRE 711; RO 01 6128; RO 67 4853; UBP 1112; UNCLASSIFIED DRUG; UNINDEXED DRUG; LIGAND; NEUROPROTECTIVE AGENT;

ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; ATTENTION DISTURBANCE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; COORDINATION DISORDER; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; GLIOMA; HUMAN; LEARNING; MEMORY; MOVEMENT (PHYSIOLOGY); MUSCLE WEAKNESS; NERVE DEGENERATION; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PARKINSON DISEASE; SCHIZOPHRENIA; SEIZURE; SENSORY STIMULATION; SOMNOLENCE; SYNAPTIC TRANSMISSION; WITHDRAWAL SYNDROME; ADDICTION; ANIMAL; DRUG EFFECT; NEOPLASM; PAIN; PHYSIOLOGY; POSTTRAUMATIC STRESS DISORDER;

ANIMALS; ANXIETY DISORDERS; HUMANS; LIGANDS; NEOPLASMS; NEUROPROTECTIVE AGENTS; PAIN; PARKINSON DISEASE; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; STRESS DISORDERS, TRAUMATIC; SUBSTANCE-RELATED DISORDERS;

EID: 32844468690     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (27)

1. Epping-Jordan, M.P., Kayak, S., Derouet, F. et al. In vivo characterization of mGluR5 positive allosteric modulators as novel treatments for schizophrenia and cognitive dysfunction. Neuropharmacology 2005, 49(Suppl. 1): 243.
2. Poli, S.M., Barbier, S., Bessif, A. et al. In vivo characterization of mGluR5 positive allosteric modulators as novel antipsychotic agents: Pharmacokinetic/pharmacodynamic correlation. Neuropharmacology 2005, 49(Suppl. 1): 266.
3. Conn, P.J., Hemstapat, A., Rodriguez, A.L. et al. Pharmacological properties and therapeutic potential of allosteric potentiators of metabotropic glutamate receptors. Neuropharmacology 2005, 49(Suppl. 1): 240.
4. Galici, R., De Paulis, T. and Conn, P.J. A novel selective mGluR2 allosteric potentiator reduces phencyclidine-induced hyperlocomotor activity and disruption of prepulse inhibition. Neuropharmacology 2005, 49(Suppl. 1): 245.
5. Corti, C., Crepaldi, L., Mion, S., Roth, A.L., Xuereb, J.H. and Ferraguti, F. Altered levels of the dimeric form of the metabotropic glutamate receptor3 (mGluR3) in the prefrontal cortex of subjects with schizophrenia. Neuropharmacology 2005, 49(Suppl. 1): 240.
6. Robbins, M.J., Starr, K.R., Honey, A. et al. Investigating the potential of the mGlu8 receptor as a drug target in schizophrenia using the specific agonist, (s)-3,4-DCPG. Neuropharmacology 2005, 49(Suppl. 1): 269.
7. Markou, A., Paterson, N., Kenny, J.P. et al. Metabotropic glutamate receptors 5 and 2/3 in nicotine reward, motivation and dependence. Neuropharmacology 2005, 49 (Suppl. 1): 255.
8. McKinzie, D.L., Rodd, Z.A., McBride, W.J. and Schoepp, D.D. mGlu receptor ligands for the treatment of addiction disorders. Neuropharmacology 2005, 49(Suppl. 1): 256.
9. Schoepp, D.D., Johnson, B.G., Wright, R.A. et al. Pharmacology of LY404039: A potent systemically active mGlu2/3 receptor agonist for psychiatric disorders. Neuropharmacology 2005, 49(Suppl. 1): 272.
10. Curry, K. Pharmacology of the novel mGluR antagonists PRE703 and PRE711. Neuropharmacology 2005, 49(Suppl. 1): 241.
11. Flor, P.J., Vassout, A., Fendt, M. et al. AMN082, the first selective mGluR7 agonist: Activation of receptor signalling via an allosteric site in the transmembrane domain modulates stress parameters in vivo. Neuropharmacology 2005, 49(Suppl. 1): 244.
12. Thakker, D.R., Hoyer, D., Schmutz, M. et al. mGluR7 plays a key role in the modulation of anxiety behavior: Evidence from mGluR7-knockout mice and siRNA-induced knockdown in the adult mouse brain. Neuropharmacology 2005, 49(Suppl. 1): 275.
13. Mrzljak, L. and Smagin, G. Neurochemistry of conditioned fear in the rat basolateral amygdala: Role of group II metabotropic glutamate receptors. Neuropharmacology 2005, 49(Suppl. 1): 259.
14. Pilc, A., Klodzinska, A., Palucha, A. et al. Anxiolytic-like responses induced by group III mGlu receptor ligands in rats. Neuropharmacology 2005, 49(Suppl. 1): 264.
15. Michelson, D., Levine, L.R., Dellva, M.A. et al. Clinical studies with mGluR2/3 agonists: LY354740 compared with placebo in patients with generalized anxiety disorder. Neuropharmacology 2005, 49(Suppl. 1): 257.
16. Bruno, V., Molinaro, G., Battaglia, G., Nicoletti, F. and Corti, C. The group-II mGlu receptor agonist, LY379268, differentially affects neuronal vulnerability in mGlu2 and mGlu3 receptor knockout mice. Neuropharmacology 2005, 49(Suppl. 1): 235.
17. Liu, F., Gong, X., Zhang, G., Marquis, K., Reinhart, P. and Andree, T.H. The inhibition of GSK3beta by a mGluR5 mediated pathway confers neuroprotection to Abeta peptides. Neuropharmacology 2005, 49(Suppl. 1): 253.
18. O'Neill, M.J. A role for metabotropic glutamate receptors in acute and chronic brain injury? Neuropharmacology 2005, 49 (Suppl. 1): 261.
19. Pshenichkin, S., Dolinska, M., Klauszinka, M., Luchenko V., Grajkowska, E. and Wroblewski, J.T. Neurotoxic and neuroprotective properties of mGluR1 receptors in neurons and transfected cells. Neuropharmacology 2005, 49(Suppl. 1): 268.
20. Guo, L., Salt, T.E., Maass, A. et al. Activation of group II mGlu receptors is neuroprotective in retinal ganglion cell apoptosis in in vivo models of glaucoma. Neuropharmacology 2005, 49(Suppl. 1): 247.
21. Amalric, M., Turle-Lorenzo, N. and Lopez, S. Metabotropic glutamate receptors: Potential pharmacology targets in Parkinson's disease treatment. Neuropharmacology 2005, 49(Suppl. 1): 231.
22. Battaglia, G., Busceti, L.C., Molinaro, G. et al. Role of metabotropic glutamate receptors in neurodegeneration/neuroprotection mechanisms in experimental animal models of Parkinsonism. Neuropharmacology 2005, 49(Suppl. 1): 232.
23. Jones, C.K., Marino, M.J., Nong, Y. et al. Modulation of the basal ganglia by metabotropic glutamate receptors: Potential novel approaches for the treatment of Parkinson's disease. Neuropharmacology 2005, 49(Suppl. 1): 251.
24. Palazzo, E., Marabese, I., de Novellis, V., Scafuro, M.A., Rossi, F. and Maione, S. mGluR8 receptors in inflammatory and neuropathic pain in mouse. Neuropharmacology 2005, 49(Suppl. 1): 262.
25. Bertorelli, R., Freduzzi, S., Nicolussi, E., Forlani, A. and Reggiani, A. Selective blockade of metabotropic glutamate subtype mGluR1 receptors induce anti-nociceptive effects. Neuropharmacology 2005, 49 (Suppl. 1): 233.
26. Arcella, A., Carpinelli, G., Battaglia, G. et al. The mGlu receptor antagonist, LY341495, reduces proliferation of glioma cells in vivo. Neuropharmacology 2005, 49(Suppl. 1): 231.
27. Iacovelli, L., Arcella, A., Spinsanti, P. et al. PHCCC, a specific enhancer of the type 4 metabotropic glutamate receptors, reduces proliferation of medulloblastoma cells. Neuropharmacology 2005, 49(Suppl. 1): 250.